Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 2Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 18Carboplatin 14Topotecan 8liposomal doxorubicin 6Cyclophosphamide 5Cisplatin 5Gemcitabine 4Docetaxel 4oregovomab 3Immunoenzyme Techniques 3Etoposide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Stem Cell Transplantation 2STA 9090 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Nivolumab 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Fulvestrant 2Fluorodeoxyglucose F18 2Flow Cytometry 2Filgrastim 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Ovarian Epithelial × denileukin diftitox × Clear all
NCT01773889 2018-04-10

A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Terminated
2 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡